ents a grim picture," said William
Jarvis, MD, principal investigator of the study and president and
co-founder of Jason and Jarvis Associates, a private consulting
firm in healthcare epidemiology. "The findings argue for immediate,
aggressive efforts to detect and prevent transmission of MRSA.
Because the true magnitude of the total MRSA burden in the U.S.
healthcare population is unknown, our objective was to provide the
first national estimate of MRSA in U.S. healthcare facilities."
The research indicated that once MRSA cases are identified,
healthcare facilities employ recommended practices to prevent
transmission of the organism, such as practicing barrier
precautions (use of gloves and gowns), hand hygiene and isolating
MRSA patients. 81 percent of patients in the study were not
identified until they presented signs or symptoms of an active
infection prompting doctors to order lab tests. This finding
implies that a significant number of patients are potentially
transmitting MRSA to healthcare workers and other patients before
the bacteria are identified.
"Quite simply this survey is a wake up call for healthcare
facilities to save lives by dedicating more resources to infection
prevention and control because the transmission of MRSA is
preventable," said Denise Murphy, president of APIC and Vice
President of Safety and Quality, and Chief Patient Safety and
Quality Officer at Barnes-Jewish Hospital at Washington University
Medical Center in St. Louis. "Some healthcare facilities are
aggressively addressing MRSA, but the scope of this public health
threat demands commitment and participation from every hospital, at
all levels of the facility. Hospitals should commit the resources
to conduct a thorough risk assessment of patient populations and
implement viable strategies to prevent MRSA and other
antimicrobial-resistant infections. These measures could help
prevent this epidemic from continuing to spiral upward and out of
control."
APIC guid
'"/>
Page: 1 2 3 Related medicine technology :1.
Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types2.
Actilyse (alteplase) Recommended by National Institute for Health
and Clinical Excellence for Treatment of Acute Ischaemic Stroke3.
Positive Results Prompt US National Cancer Institute to Make Glivec
Available to Patients in Post-Surgical GIST Study4.
Positive Results Prompt US National Cancer Institute to Make
Gleevec Available To Patients in Post-Surgical Gist Study5.
First-of-its-Kind National Report Reveals Estimated High Prevalence
and Heavy Cost of Type 2 Diabetes Complications in America6.
Research Results on FluMist Presented at National Association of
Pediatric Nurse Practitioners Conference7.
Protox Announces Publication in Journal of the National Cancer
Institute Supporting PRX302 as Treatment for Prostatic Diseases8.
Calando Pharmaceuticals Publishes the First Non-Human Primate Study
on Targeted, Systemic Delivery of siRNA in National Academy of
Sciences Journal9.
Advanced Magnetics Announces Presentation of Ferumoxytol Data at
the National Kidney Foundation 2007 Spring Clinical Meetings10.
Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance11.
Nationwide MRSA Prevalence Study to Demonstrate Full Scope of
Superbug Threat Facing U.S. Healthcare Facilities and Patients